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Bing Chen1†, Hongbin Li1†, Xiao Zeng1, Pengbo Yang1, Xinyu Liu1, Xia Zhao1,2 and Shufang Liang1*Abstract
Advanced studies of microRNAs (miRNAs) have revealed their manifold biological functions, including control of cell
proliferation, cell cycle and cell death. However, it seems that their roles as key regulators of metabolism have
drawn more and more attention in the recent years. Cancer cells display increased metabolic autonomy in
comparison to non-transformed cells, taking up nutrients and metabolizing them in pathways that support growth
and proliferation. MiRNAs regulate cell metabolic processes through complicated mechanisms, including directly
targeting key enzymes or transporters of metabolic processes and regulating transcription factors, oncogenes /
tumor suppressors as well as multiple oncogenic signaling pathways. MiRNAs like miR-375, miR-143, miR-14 and
miR-29b participate in controlling cancer cell metabolism by regulating the expression of genes whose protein
products either directly regulate metabolic machinery or indirectly modulate the expression of metabolic enzymes,
serving as master regulators, which will hopefully lead to a new therapeutic strategy for malignant cancer. This
review focuses on miRNA regulations of cancer cell metabolism,including glucose uptake, glycolysis, tricarboxylic
acid cycle and insulin production, lipid metabolism and amino acid biogenesis, as well as several oncogenic
signaling pathways. Furthermore, the challenges of miRNA-based strategies for cancer diagnosis, prognosis and
therapeutics have been discussed.
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MicroRNAs (miRNAs) are endogenous ~22 nt RNAs that
can play important regulatory roles in a variety of biological
processes. They are genome-encoded, endogenous negative
regulators of translation and mRNA stability originating
from long primary transcripts with local hairpin structures
[1]. Conserved seed pairing indicates that over one third of
human genes appear to be conserved miRNA targets [2].
MiRNAs are involved in cell proliferation, intercellular sig-
naling, cell growth, cell death [3,4], cellular differentiation,
apoptosis [5] and cellular metabolism [6,7]. Meanwhile they
have emerged as key post-transcriptional regulators of gene
expression, and their dysregulation may lead to abnormal
gene expression, which is associated to human diseases
such as cancer. For example, miR-378* (expressed from the
3'-arm), which mediates metabolic shift in breast cancer
cells, leading to a reduction in tricarboxylic acid cycle gene
expression and oxygen consumption as well as an increase* Correspondence: zizi2006@scu.edu.cn
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reproduction in any medium, provided the orin lactate production, via the PGC-1β/ERRγ transcriptional
pathway [8].
Recent studies have shown that miRNAs play impor-
tant roles in energy metabolism, including glucose and
lipid metabolism and amino acid biogenesis [9] (Table 1).
Besides, miRNAs are also able to recognize and modu-
late metabolic factors in transcriptional levels, relevant
both in non-neoplastic and in cancer cells [10]. The
altered metabolism of tumor cells may be a potential
means to evade programmed cell death in order to favor
survival and growth. The best characterized metabolic
phenotype observed in tumor cells is the Warburg effect,
in which the deregulation of miRNAs contributes to
high glycolysis [11,12].
MiRNAs participate in controlling cancer cell metabo-
lism by regulating the expression of genes whose protein
products either directly regulate metabolic machinery or
indirectly modulate the expression of metabolic enzymes,
serving as master regulators. Generally, miRNA signatures
may distinguish physiological, pathologic from cancerous
states, which could be useful biomarkers in targeted
therapeutic-diagnostics for cancer. Therefore, this review
will focus on discussing the important roles of miRNAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of miRNA regulation in energy metabolism
miRNA Tissue / cell lines miRNA functions Target gene/Pathway Reference
miR-103/
107
obese mice: ob/ob mice
and diet-induced-obese (DIO) C57BL/6J mice
regulate insulin sensitivity caveolin-1 41
miR-122 primary mouse hepatocytes
and AML12
regulator of cholesterol and
fatty-acid metabolism
23,26,38,49,5054,60
miR-133 293FT cells decreased GLUT4 expression
and reduced insulin-mediated
glucose uptake in cardio
myocytes
31,34
miR-14 Drosophila regulate fat metabolism 36
miR-143 liver of obese mouse models impairs insulin-stimulated
AKT activation and glucose
homeostasis
Orp8 / Akt pathway 12,26,35,36, 37,91
miR-146 diabetic db/db mice islets / MIN6B1 cells cell death Irak1 & Traf6 / AP-1 pathway 52
miR-15a/
16-1
leukemic cell line model (MEG-01)
and in primary CLL samples
directly or indirectly affect
apoptosis and cell cycle
MCL1, BCL2, ETS1,or JUN 27





miR-210 human pulmonary arterial endothelial cells
(HPAECs)
cellular metabolism and
adaptation to cellular stress
ISCU1/2 42




miR-277 D. melanogaster a metabolic switch controlling
amino acid catabolism
61
miR-27a 3T3-L1 suppress adipocyte
differentiation
PPARγ 51
Male C57BL/6J mice and 3T3-L1 cells a negative regulator of
adipocyte differentiation
miR-29b human kidney cells (HEK293) control metabolic pathway
of amino acid catabolism
mRNA for DBT 62
miR-335 liver of obese mouse affects adipocyte
differentiation
and lipid accumulation
PPARγ & aP2 53
miR-33a/b mouse peritoneal macrophages regulate both HDL biogenesis
in the liver and cellular
cholesterol efflux
ABCA1 58
miR-34a diabetic db/db mice islets / MIN6B1 cells sensitization to apoptosis
and impaired nutrient-induced
secretion
BclII / p53 pathway 52,68
miR-370 liver of mouse affects lipid metabolism Cpt1α 54
miR-375 pancreatic endocrine cells (MIN6 cells) suppressed glucose-induced
insulin secretion
Mtpn 45,76
miR-378 NMuMG cells and NT2196 reduce tricarboxylic acid cycle
gene expression and oxygen
consumption as well as
increase
lactate production
ERRγ and GABPA 8
INS-1E cells/primary rat islets decreased glucose-stimulatory
action on insulin gene
expression
and DNA synthesis
Cell growth Eef1e1 76
cell growth Cadm1 76
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regulate cell cycle and
cellular proliferation





Id3 / VEGF pathway or MAPK
pathway
76,79
regulate cell growth/survival Rasd1 / Ras pathway 76,81
cell-cell signaling Rgs16 76
mitochondrial morphology
and cristae structure,





Chen et al. Journal of Translational Medicine 2012, 10:228 Page 3 of 12
http://www.translational-medicine.com/content/10/1/228expression and deregulation in the altered metabolism in
cancer cells.MiRNAs involved in cancer cell metabolism
The biogenesis of miRNAs is tightly associated with
their action mechanism (Figure 1). Most miRNAs
derived from independent transcription units [13,14]
and are encoded by a bewildering array of genes. Their
transcription is typically performed by RNA polymerase
II, with transcripts capped and polyadenylated. The
resulting primary or pri-miRNA transcript extends both
5’ and 3’ from the miRNA sequence. The sequential pro-
cessing reaction excises the stem-loop from the remain-
der of the transcript to create a pre-miRNA product,
which occurs in the nucleus and is mostly carried out by
a nuclear member of the RNase III family (Drosha). The
following step excises the terminal loop from the pre-
miRNA stem to create a mature miRNA duplex of
approximately 22 bp length, which is carried out by the
canonical Dicer enzyme in the cytoplasm. Either of the
strands becomes stably associated with RNA-induced
silenced complex (RISC), which can be called miRISC
complex [15,16]. The miRISC complex acts as a regula-
tor of target gene by specially recognizing and regulating
particular mRNAs to inhibit target genes [17].
A shift in glucose metabolism from oxidative phosphor-
ylation to aerobic glycolysis was a key biochemical hall-
mark of tumor cells [18,19]. The altered metabolism was
called “Warburg phenomenon”, which consists of an in-
crease in glycolysis maintained in conditions of high oxy-
gen tension and gives rise to enhanced lactate production
[20,21]. Metabolic shift in cancer cells seems to be influ-
enced by oncogene and tumor suppressor networks [22].
What’s more, most of these tumor suppressors are miRNA
targets. For example, phosphatidylinositol 3-kinase, a lipid
kinase that regulates the levels of phosphorylated phos-
phatidylinositol at the plasma membrane, plays a key rolein cancer cell metabolism, which is targeted by miR-320,
miR-123a, miR-422, miR-506 and miR-136.
There are several lines of evidence that many key
molecules in cell metabolism are miRNA targets, thus
giving a clue that miRNA regulates cell metabolism.
Since miRNAs regulate a substantial fraction of genes in
animal genomes, Tibiche and Wang systematically ana-
lyzed the human metabolic network by integrating
miRNA target genes into the network [23]. They per-
formed randomization tests to determine whether a
multiple-gene-node is significantly regulated by miRNAs
and defined 79 multiple-gene-nodes as miRNA targets.
They merged the miRNA targets of single-gene-nodes
with the multiple-gene-nodes, and found that 238 (22%)
nodes are miRNA targets. The functional association
analysis of miRNAs and metabolic pathways uncovered
that miRNAs predominantly regulate central metabolic
pathways such as amino acid biosynthesis, certain sugar
and lipid metabolism (Figure 2).
Regulation of metabolic activity by miRNAs
MiRNAs regulate cell metabolic processes through com-
plicated mechanisms, including directly targeting key
molecules (transporters or enzymes / kinases) of meta-
bolic processes and regulating multiple oncogenic sig-
naling pathways (Figure 3). MiRNAs could directly
modulate the expression of metabolic transporters or en-
zyme activities. In addition, MiRNAs also play pivotal
roles in the expression level of transcription factors and
oncogenes or tumor suppressors, including p53, c-Myc,
AMPK and AKT signaling pathway.
The molecular mechanisms driving the Warburg effect
in cancer cells were taken as an example to explain
miRNA regulation in energy metabolism. As shown in
Figure 3, several miRNAs affect gene transcription and ex-
pression of glucose transporters (GLUTs) which are re-
sponsible for transporting glucose into cytoplasm. In the
initial step of glucose metabolism, glucose could be
Figure 1 Biological functions of miRNA. The first step is the nuclear cleavage of the pri-miRNA, with a ~60-70 nt stem loop intermediate
liberated, known as the miRNA precursor, or the pre-miRNA. Then this pre-miRNA is actively transported from the nucleus to the cytoplasm by
Ran-GTP and export receptor. One end of the mature miRNA was cut by Drosha in nuclear and the other end is processed in the cytoplasm by
the enzyme Dicer. Either of the strands becomes stably associated with RNA-induced silenced complex (RISC), which can be called miRISC
complex. The miRISC complex inhibits the target genes by (A) repressing initiation at the cap recognition, (B) inducing deadenylation of mRNA
and thereby inhibiting circularization of mRNA, (C) inducing ribosomes to drop off prematurely thus repressing the translation initiation and
(D) promoting mRNA degradation.
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GLUT4 which is a target of miR-133 [24] or miR-195-5p
[25]. Thus, miRNAs could directly regulate intracellular
glucose levels. In the following step, the hexokinase 2
(HK2), the first rate-limiting enzyme of glycolysis, is
among the top list of genes predicted and potentially regu-
lated by multiple miRNAs including miR-143 [26]. Along
the glycolysis reaction chain, fructose 1,6-bisphosphate is
broken down into glyceraldehyde 3-phosphate and dihy-
droxyacetone phosphate, which is catalyzed by aldolase A
(Aldo A) in the reversible aldol reaction. While the en-
zyme Aldo A is down-regulated by miR-15a/16-1cluster
[27]. And the specific miRNAs in glucose metabolism will
be summarized into 4 subtitles as follows, includingmiRNA effects on glucose uptake, glycolysis, tricarboxylic
acid (TCA) cycle and insulin regulation.
On the other hand, aerobic glycolysis in tumor cells is
driven by multiple miRNA-involved oncogenic signaling
pathways. For example, AKT, a cardinal node in diverse
signaling cascades, is regulated by miR-21 [28], which sti-
mulates glycolysis by directly regulating glycolytic
enzymes and activating downstream mammalian target of
rapamycin (mTOR) activity. The regulation of several spe-
cifically signaling pathways involved in cancer cell metab-
olism by miRNAs will be introduced in detail in the
second section of this review. Therefore, mRNA dysregu-
lation in any step of metabolic processes contributes to
metabolic abnormalities and even cancer development.
Figure 2 The main miRNAs involved in metabolism of glucose,
lipid and amino acid, as well as metabolism-associated
oncogenic signaling pathways. Among the total 60 miRNAs
mentioned in the text, more than 20 miRNAs, including miR-375,
miR-133, miR-199a, miR-138, etc., involve in glucose metabolism.
And miR-14, miR-27a, miR-34a, miR-146, miR-335, miR-370, miR-122
and miR-33a/b function on lipid metabolism, including participating
in controlling Acetyl-CoA and plasma cholesterol. While several
miRNAs (miR-23b*, miR-29a/b, miR-277 etc.) play functions in amino
acid metabolism mainly through regulating acyltransferase and α-
ketoacid dehydrogenase. In addition, about 29% of the mentioned
miRNAs (miR-125b, miR-504, miR-25, miR-30d, etc.) participate in
metabolism-associated oncogenic signaling pathways.
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MiRNAs affect glucose uptake
GLUTs (or SLC2A) are a wide group of membrane pro-
teins that facilitate the transport of glucose over a plasma
membrane in most mammalian cells. To date, 14 mem-
bers of GLUTs have been identified [29]. The amounts of
the GLUT1, GLUT2, and GLUT3 transcripts were ele-
vated in most cancer tissues, while mRNA levels of
GLUT4 and GLUT5 were below sensitivity in these cancer
tissues. The potential effects of the GLUTs level seem to
facilitate accelerated metabolism, high glucose require-
ments, and increased glucose uptake in malignant cells.
Several factors have been implicated in the regulation of
their expressions. Hormonal, for example, ovarian hor-
mones, particularly estrogen, could provide a mechanism
of GLUT regulation [30]. In addition, hypoxic also drives
GLUT expression [31] as well as metabolic-stress-induced
signaling pathways, such as adenosine monophosphate-
activated protein kinase (AMPK), triggering upregulation
of GLUT receptors [32].
MiRNAs could regulate glucose uptake via altering the
GLUTs expressions. MiR-133 has been confirmed to
regulate the expression of GLUT4 by targeting KLF15 ina rat model [31]. A study in renal cell carcinoma
demonstrated that down-regulated miR-199a, miR-138,
miR-150 and miR-532-5p were correlated with an increased
expression of GLUT-1, whereas an increased expression of
miR-130b, miR-19a, miR-19b and miR-301a can result in
the down-regulation of GLUT-1 [32]. MiR-195-5p has been
identified as a direct regulator of GLUT3 by targeting
GLUT3 3’-untranslated region in bladder cancer T24 cells
[33]. Interestingly, miR-19a and miR-133a are altered in
colorectal carcinoma [34], and their roles in regulating
GLUT expression might explain the disordered metabolism
in colorectal carcinoma. In addition, miR-130b is highly
down-regulated in pancreatic tumors, and its role in regu-
lating GLUT-1 expression might explain the increased
glucose uptake in pancreatic adenocarcinoma [35].Functions of miRNAs on glycolysis
Studies show that miRNAs regulate the irreversible steps
in glycolysis, especially the key enzymes [33]. For example,
miR-143, as an essential regulator of glycolysis, modulates
glycolysis via targeting HK2 [12], which phosphorylates
glucose to produce glucose 6-phosphate, thus committing
glucose to the glycolytic pathway. Recently new protein
targets of miRNAs have been identified by sensitive mass
spectrometric studies. The oxysterol-binding-protein-
related-protein 8 has been revealed as a target of miR-143
by quantitative mass spectrometry analysis [34]. For ex-
ample, miR-155 could repress miR-143 thereby upregulat-
ing the expression of HK2 at the post-transcriptional level,
except by activating the signal transducer and activator of
transcription 3, a transcriptional activator for HK2 [35].
Besides, miR-143 inhibits the expression of HK2 both in
primary keratinocytes and in head and neck squamous cell
carcinoma-derived cell lines [36]. What’s more, HK2 has
been validated as a miR-143 target and thus miR-143
could affect glucose metabolism in colon cancer cells [37].
Likewise, miR-143 has also been identified as an essential
regulator of cancer glycolysis via targeting HK2 in human
lung cancer [12]. Interestingly, the above articles were
published almost at the same time. These reports all illu-
strated that miR-143 targets HK2 to regulate glucose me-
tabolism in cancer cells, and it is a potential cancer
therapeutic target.
Except for targeting the irreversible rate-limiting steps,
miRNAs also regulate other important intermediate
steps in the glycolysis pathway. The enzyme Aldo A cat-
alyzes a reversible aldol reaction in which fructose 1,6-
bisphosphate is broken down into glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate. In this
process, miR-122 was predicted to target Aldo A [26,38],
and the miR-15a/16-1 cluster could reduce the levels of
Aldo A [27]. Thus miR-122 and miR-15a/16-1 cluster
are involved in glycolysis in cancer cells.
Figure 3 MicroRNAs regulate cell metabolism by targeting key metabolic enzymes and multiple oncogenic signaling pathways. MiRNAs
could regulate cell metabolism by modulating the expression of metabolic transporters (like GLUT) or enzymes (HK2, ALDOA and PDK1) and
acting on p53, c-Myc and AKT/mTOR signaling pathways. The steps regulated by miRNAs are indicated by red circular arrows, and the related
miRNAs are listed in the bracket. FASN, fatty acid synthase; GLUT, glucose transporter; HIF, hypoxia-inducible factor; LAT1, L-type amino acid
transporter 1; LDH-A, lactate dehydrogenase isoform A; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, pyruvate
dehydrogenase kinase; PI3K, phosphatidylinositol 3-kinase.
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As described before, aerobic glycolysis in tumor cells im-
plies conversion of glucose into pyruvate and subse-
quently into lactic acid [39]. Acetyl-CoA tends to be
introduced into a truncated TCA cycle, with the net re-
sult that acetyl-CoA is exported into cytosol. In this
truncated TCA cycle, citrate is preferentially exported to
cytosol and cleaved by ATP citrate lyase (ACL) to gener-
ate oxaloacetate and acetyl-CoA. Oxaloacetate is
reduced to malate, then reimported into mitochondria
and reconverted to oxaloacetate in the matrix (while
generating NADH that represses the TCA cycle), and it
reacts with acetyl-CoA to complete the substrate cycle.
A shift in glucose metabolism from oxidative phos-
phorylation to aerobic glycolysis has been accepted as a
common event in cancer. This process implicates differ-
ent kinds of energy production pathways are mediatedby diverse regulators, including miRNAs [40]. For ex-
ample, miR-103 and miR-107 have been predicted in
regulating acetyl CoA and lipid levels in cellular systems
[41]. Additionally, a set of miRNAs, including miR-152,
miR-148a, miR-148b, miR-299-5p, miR-19b, miR-122a,
miR-421, miR-494 and miR-19a [23], regulate the citrate
synthase gene which encodes a major enzyme in TCA
cycle. Besides, miR-210, a miRNA specifically induced
by HIF-1α during hypoxia, represses the iron-sulfur
cluster assembly proteins (ISCU1/2) [42]. ISCU1/2 facili-
tates the assembly of [4Fe-4S] and [2Fe-2S] iron-sulfur
clusters, which are incorporated into the TCA cycle
related enzymes, like aconitase. Thereby, the effect of
miR-210 on ISCU1/2 leads to decrease the activity of
TCA cycle. Furthermore, miRNAs also regulate TCA
cycle indirectly by acting on transcription factors Myc
and HIF etc.
Figure 4 MiRNA-based diagnosis strategies for cancer. The workflow of detecting cancer based on miRNA profiling is included sample
(serum or tissue) collection, miRNA expression profiling, data analysis of miRNA expression level and cancer risk assessment. The level of the at
least one miRNA gene product can be measured using a variety of techniques (microRNA chip, quantitative or semi-quantitative RT-PCR, northern
blot analysis, solution hybridization detection etc.) to provide a profile for the test sample. The level of at least one miRNA gene product in a test
sample from the subject is compared to that in a control sample. A significantly increased or decreased alteration in the level of the miRNA gene
product in the detected sample is indicative of the subject either having or being at risk for developing a cancer.
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MiRNAs have shown to modulate the secretion, action
and sensitivity of insulin to affect glucose uptake and
production [43]. Insulin acts in concerting with glucagon
to maintain glucose homeostasis. MiR-375 has been
identified to be expressed selectively in pancreatic endo-
crine cell lines. The overexpression of miR-375 results in
suppressed glucose-stimulated insulin secretion and its
inhibition enhances insulin secretion [44]. Besides, Myo-
trophin, a protein implicated in exocytosis, was a vali-
dated target of miR-375. Similarly, a tantalizing new
candidate target of miR-375, 3’-phosphoinositide-
dependent protein kinase-1, is a key molecule in PI3-
kinase signaling in pancreatic β-cells [45].
MiRNAs affect lipid metabolism
Several miRNAs participate in the regulation of lipid
metabolism. The deletion of miR-14 increased the levels
of triacylglycerol and diacylglycerol while its overexpres-
sion resulted in the converse effect, suggesting that
miR-14 acts as a regulator of fat metabolism [46].Additionally, there’s evidence that miRNAs are involved
in the development and maturation of adipocytes from
precursor cells called pre-adipocytes [47,48]. MiR-122
could act as an important regulator of cholesterol and
fatty-acid metabolism in the adult liver [49]. The inhib-
ition of miR-122 in normal mice resulted in reduced
plasma cholesterol levels, increased hepatic fatty-acid
oxidation, and a decrease in hepatic fatty-acid and chol-
esterol synthesis rates, but resulted in decreased plasma
cholesterol levels, a significant improvement in liver
steatosis and reductions in several lipogenic genes. After
that, miR-122 has been found as an important regulator
in liver lipid metabolism [50]. In the recent article,
miR-27a has been revealed to be involved in adipocyte
differentiation by binding to the PPARγ 3’-UTR, whose se-
quence motifs are highly conserved in mammals [51]. All
these studies indicate that miRNA plays an important role
in lipid metabolism.
The changes of miRNA expression in β-cell under
physiopathological conditions have been illustrated be-
fore. And at least part of the detrimental effects of
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ation in the levels of specific miRNAs, like miR-34a and
miR-146 [52]. Apart from that, the up-regulation of
miR-335 has also been found in obesity by microarray
analysis [53]. Besides, the expression of miR-335 was up-
regulated in liver and white adipose tissue in obese mice,
which was associated with an elevated body, liver and
WAT weight, and hepatic triglyceride and cholesterol.
Additionally, miR-370 acting via miR-122 may accumu-
late hepatic triglycerides by modulating initially the ex-
pression of SREBP-1c, DGAT2, and Cpt1α and,
subsequently, the expression of other genes that affect
lipid metabolism [54].
Recently, miR-33a/b has been discovered to govern
cholesterol / lipid metabolism and energy homeostasis
[55]. MiR-33a/b embeds within intron sequences of the
human SREBF genes and controls the levels of ATP-
binding cassette transporter ABCA1, a cholesterol efflux
pump critical for high-density lipoprotein synthesis and
reversing cholesterol transport from peripheral tissues
[56,57]. MiR-33a/b also acts in the lipid homeostasis
pathway by controlling the expression of fatty acid
β-oxidation genes including carnitine O-octanoyltransfer-
ase, hydroxyacyl-CoA-dehydrogenase, and carnitine pal-
mitoyltransferase 1A, as well as energy homeostasis
regulators AMPK a1, SIRT6, and insulin receptor sub-
strate 2 [58]. These reports bring us a further view of
miRNA function on lipid metabolism.
Effects of miRNA in amino acid metabolism
Amino acid metabolism is linked to biosynthesis of pro-
tein, nucleotide and lipids, redox homeostasis, and en-
ergy metabolism. MiR-23b* (expressed from the 3'-arm)
mediates proline oxidase, the first enzyme in proline ca-
tabolism, down-regulation in human kidney tumors [59].
Furthermore, the metabolic link between proline and
glutamine afforded by Myc emphasizes the complexity
of tumor metabolism. While miR-122 was reported to
downregulate the high affinity cationic amino acid trans-
porter CAT-1 [60], thereby regulating amino acid metab-
olism. Involving evidences have been found in
Drosophila, where miR-277 plays a role as a metabolic
switch controlling amino acid catabolism by bioinfor-
matics approaches [61]. Additionally, miR29b has been
identified to control the component of the branched
chain a-ketoacid dehydrogenase complex, which cata-
lyzes the irreversible step in branched chain amino acids
(including leucine, isoleucine and valine) catabolism
[62], suggesting that miR-29b exerts effects of control-
ling on amino acid catabolism.
miRNA regulation of signaling pathways in cell metabolism
The intertwined connections between aberrant expres-
sion of microRNAs and unbalanced signaling pathwayscontribute to abnormal cell metabolism and carcinogen-
esis. The specific p53, c-Myc, AMPK and AKT signaling
pathways are included to clarify their roles in miRNA-
mediated metabolism.
p53 pathway
p53, one of the most common tumour suppressor genes,
functions to prevent tumour development by inhibiting
the outgrowth of stressed or damaged cells. In addition
to well established functions to block cell proliferation,
recent studies have revealed regulation roles for p53
involved in metabolism [63]. The p53 can inhibit the ex-
pression of GLUT-1, GLUT-4, phosphoglyceromutase
and TIGAR to affect glycolysis. TIGAR is TP53-induced
glycolysis and apoptosis regulator protein, and it inhibits
the glycolytic enzyme PFKFB2 [64]. Additonally, p53
could also activate the expression of synthesis of cyto-
chrome c oxidase 2 at transcriptional level [65] and in-
duce the expression of the ribonucleotide reductase
subunit p53R2 [66], leading to the restraint on glycolytic
rate.
Several miRNAs are able to control p53 activity. The
miR- 125b has been identified as a negative regulator of
p53 in both zebrafish and human [67]. To date, miRNAs
including miR-125b, miR-504, miR-25, miR-30d, miR-34a,
miR-122, miR-29, miR-192, miR-194 and miR-215 have
been shown to regulate p53 abundance and/or activity.
Among these, miR-125b, miR-504, miR-25 and miR-30d
negatively regulate p53 by binding to its 3'UTR whereas
the others indirectly influence p53 abundance and/or
activity by regulating the regulators of p53 [68]. The func-
tions of these miRNAs on p53 give a clue of their effects
in cancer cell metabolism.
c-Myc pathway
The c-Myc is a transcription factor that regulates the ex-
pression of genes involved in nucleotide metabolism,
DNA replication, and ribosomal and mitochondrial bio-
genesis. Studies in the past few years have led to the
identification of miRNAs as novel regulators of c-Myc
activity. A mutated version of Myc leads to the unregu-
lated expression of many genes, some of which are
involved in cell proliferation and results in the formation
of cancer [69]. For example, c-Myc has crucial roles in
glutamine metabolism mediated by miR-23b [70]. More-
over, in concerts with HIF1 to regulate glucose uptake
and glycolytic enzyme expression, thus favouring tumour
growth in hostile environments [71].
The regulation of Myc mRNA by let-7a has been con-
firmed [72]. Similiarly, the overexpression of let-7a can
inhibit the growth of lung cancer transplanted subcuta-
neously in nude mice by suppression of k-Ras and c-
Myc [73]. Inspiringly, c-Myc transcriptionally represses
miR-23a and miR-23b, resulting in increased expression
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tabolism through increased mitochondrial glutaminase
expression [6].
AMPK pathway
AMPK acts as a metabolic master switch regulating sev-
eral intracellular systems including the cellular uptake of
glucose, the β-oxidation of fatty acids and the biogenesis
of GLUT4 and mitochondria [74]. AMPK controls glu-
cose homeostasis by regulating metabolism in multiple
peripheral tissues, such as skeletal muscle, liver, adipose
tissues, and pancreatic β cells [75].
The functions of miR-375 on glucose homeostasis
have been studied [76]. Total 381 putative direct targets
of miR-375 were selected, which contained a miR-375
recognition motif, and confirmed 10 of these genes, in-
volving caveolin1 [77,78], inhibitor of DNA binding 3
[79,80], Smarca2, Ras-dexamethasone-induced-1 [81],
regulator of G protein signaling 16 [82], eukaryotic
elongation factor 1 epsilon 1, apoptosis-inducing factor,
mitochondrion-associated 1, cell adhesion molecule 1,
HuD antigen [83], and complement component 1 q sub-
component binding protein. Published data have shown
that some of these genes play a role in AMPK signaling,
inducing apoptosis and inhibiting normal developmental
growth processes or the proliferation of tumors.
AKT pathway
The PI3K/AKT/mTOR pathway is an intracellular sig-
nalling pathway, which is important in apoptosis. It has
risen to prominence as a key regulator of cell cycle pro-
liferation, growth, survival, protein synthesis, and glu-
cose metabolism [84]. Activation of PI3K leads to the
activation of downstream effectors including Akt and
mTOR that support cellular biosynthesis [85-87].
Enhanced PI3K/Akt signal increases the expression
of nutrient transporters, enabling increased uptake of
glucose, amino acids, and other nutrients. Additionally,
Akt-dependent stimulation of hexokinase and phospho-
fructokinase drives glycolysis. Furthermore, AKT-involved
signaling enhances transcription of genes to involve in
glycolysis and lipid genesis [88-90].
Regulation of this pathway by miRNAs mainly results
in altered glucose and lipid metabolism. For example,
miR-21, which inhibits a negative regulator PTEN of the
PIK/AKT pathway, is induced in gemcitabine-resistant
pancreatic cancer cells [28]. And AKT pathway can in-
volve in glycolysis by directly regulating glycolytic
enzymes and activating downstream mTOR activity.
Similiarly, ORP8 has been identied as an miR-143 target
and the reduction of ORP8 expression in cultured liver
cells impairs the ability of insulin to induce AKT activa-
tion, revealing an ORP8-dependent mechanism of AKT
regulation [91].MiRNAs affect multiple targets in regulatory networks
Certain miRNAs have also been shown to affect multiple
targets in linear pathways or interconnected nodes in
regulatory networks [25], thereby exerting a larger
cumulative effect [9,55]. For example, miR-33a and miR-
33b, as described before, interact with the SREBP
transcription factors to regulate cholesterol and lipid
homeostasis. Furthermore, they may also influence insu-
lin signaling and glucose regulation by targeting IRS2,
SIRT6 and AMPK α1 [58]. MiR-34a, a miRNA that may
have important function in a network with SIRT1 and
p53, has additionally been implicated in cholesterol, lipid
and energy homeostasis [52,68]. MiRNAs typically have
rather modest effects on target protein levels, and com-
binatorial actions on multiple functionally related targets
are probably required for single miRNAs to significantly
influence a complex biological process such as metabolic
homeostasis.
MiRNAs as biomarkers for human cancer
By targeting and controlling the expression of mRNA,
miRNAs can control highly complex signal transduction
pathways and multiple metabolic processes, which are
usually involved in different oncogenic pathways [92].
The knowledge that miRNA expression is frequently
dysregulated in cancer has uncovered an entirely new
repertoire of molecular factors upstream of gene expres-
sion, with exciting potential as novel biomarkers and
therapeutic targets in cancer [93]. Exploiting the unique
characteristics of these molecules including their stabil-
ity, tissue specificity, ease of detection and manipulation,
will bring clinicians ever closer to achieving the goal of
individualized cancer treatment [94].
On the one hand, miRNAs are produced in a tissue-
specific manner, and changes in miRNA within a tissue
type can be correlated with disease status. The tissue
concentrations of specific miRNAs have been associated
with tumor invasiveness, metastatic potential, and other
clinical characteristics for several types of cancers, in-
cluding chronic lymphocytic leukemia, and breast, colo-
rectal, hepatic, lung, pancreatic, and prostate cancers
[95]. On the other hand, there has been an accumulating
body of evidence to support circulating miRNAs as non-
invasive, sensitive biomarkers of disease states, partic-
ularly cancers (breast, lung, pancreas, ovarian, and
prostate) [96]. For example, miR-9 and miR-9* (expressed
from the 3' mature sequence), mostly neuronal and thus
expressed in central nervous system tumors but absent
in other tumors, present their potential as tumor mar-
kers [97]. In addition, the reduced levels of miR-126,
members of the miR-17-92 cluster, inflammation-related
miR-155, and smooth muscle-enriched miR-145 in
patients with coronary artery disease compared with
healthy controls [98]. What’s more, published data
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potential as novel noninvasive biomarkers for early de-
tection of colorectal carcinoma [99].
Furthermore, since they are abundant in blood, easy to
measure, highly stable and disease associated, serum
microRNAs are attractive disease biomarkers [100].
There have been over 200 publications on circulating
miRNA in cancers including prostate, breast, colon,
lung, ovarian and leukemia since 2008. Considering the
sources of variation, state of microRNA in plasma and
origin and implications for disease specificity, miRNA
expression profiles of potential patients could be
assessed by measuring circulating miRNAs in patient
serum. This profile could be hopefully used for early de-
tection of cancer.
Conclusion and perspective
MiRNAs are important regulators of numerous aspects
of metabolic homeostasis, physiology and disease. In
general, miRNAs could mainly have two ways to regulate
cellular metabolism. MiRNAs could regulate transcrip-
tion factors or signaling proteins, which in turn regulate
metabolic enzymes. Alternatively, miRNAs could regu-
late the production of certain metabolites by directly
regulating the genes that encode metabolic enzymes
[101]. In addition, miRNAs could regulate mRNAs
through chromatin remodeling [102]. The emergence of
miRNAs as important regulators of metabolism has gar-
nered much interest not only from a scientific point of
view but also from a clinical perspective. The function of
miRNAs on cellular metabolism reveals molecular strat-
egies for controlling metabolic flux by miRNAs in living
organisms, thus lighting up one aspect of miRNA thera-
peutics. MiRNAs are promising in the diagnosis of can-
cer, drug target identification and clinical treatment in
the future (Figure 4). The use of miRNAs, such as oligo-
nucleotide complementary [103] or antisense oligonu-
cleotides [104] in miRNA inhibition, to suppress cell
metabolism altering will hopefully lead to a new thera-
peutic strategy for malignant cancer [105,106]. For ex-
ample, endothelial miR-126 is deregulated in patients
with type 2 diabetes, which may ultimately lead to novel
biomarkers for risk estimation and classification and
could be exploited for miRNA-based therapeutic inter-
ventions of vascular complications associated with this
disease [107].
So far, a variety of new strategies to identify and
characterize the targets of individual miRNAs have been
developed. Because miRNAs can also regulate other
non-coding RNAs, these interactions will increase the
complexity of gene regulation. Moreover, cost-effective
miRNA profiling strategies and larger studies are needed
to determine its advantage for cancer diagnosis. Add-
itionally, a new class of miRNA-based drugs that arecapable of targeting molecules outside the range of trad-
itional medicinal chemistry, their clinical implementa-
tion will require improvements in drug composition and
delivery. Since these challenges lie on the way, molecular
strategies for cancer therapy by miRNAs are still in their
infancy. Nevertheless, the successful development of
miRNA biology technologies could ultimately translate
our understanding of miRNA functions in cancer into
strategies for the control of cancer.
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